AbbVie: Hepatitis C trials
The registry lists 109 Hepatitis C studies with AbbVie as lead sponsor. 1 are open to participants now and 90 have results posted.
Phase 1 2Phase 2 26Phase 3 55No phase 32(a study in two phases counts in both)
Studies
Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Standard for Re-examination of New DrugsCompletedNCT03201718
- Expanded Access to Glecaprevir/ PibrentasvirApproved for marketingNCT03123965
- Drug Use-Results Survey in Participants Infected With Hepatitis C Virus Genotype 2CompletedNCT02945228
- Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD)WithdrawnNCT02806362Phase 3
- Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1CompletedNCT02629172
- The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese SubjectsCompletedNCT02581020
- A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 StudiesCompletedNCT00872196Phase 2
- Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1CompletedNCT00850044Phase 1
- Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected SubjectsCompletedNCT00696904Phase 1